西田　幸代

写真a

所属

医学部 病院管理学

職名

助教
このページの先頭へ▲

researchmapの所属 【 表示 ／ 非表示 】

  • 札幌医科大学   病院管理学   講師  

このページの先頭へ▲
 

論文 【 表示 ／ 非表示 】

  • Expression of hepatocyte growth factor in prostate cancer may indicate a biochemical recurrence after radical prostatectomy.

    Sachiyo Nishida, Yoshihiko Hirohashi, Toshihiko Torigoe, Masanori Nojima, Ryuta Inoue, Hiroshi Kitamura, Toshiaki Tanaka, Hiroko Asanuma, Noriyuki Sato, Naoya Masumori

    Anticancer research   35 ( 1 ) 413 - 8  2015年01月  [国際誌]

    担当区分：   筆頭著者

    　概要を見る

    We previously found that prostate cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) express hepatocyte growth factor (HGF) and that the HGF/c-MET proto-oncogene product (c-MET) signal has a role in the maintenance of prostate CSCs/CICs in an autocrine fashion. HGF is, thus, a novel marker for prostate CSCs/CICs. We hypothesized that high expression of HGF might be related to early recurrence of prostate cancer after radical prostatectomy, and the purpose of the present study was to evaluate the relationship between expression of HGF in prostate tissues and biochemical recurrence after radical prostatectomy. One hundred-one patients with prostate cancer who underwent open or laparoscopic radical prostatectomy from November 2008 to October 2011 with an adequate prostate-specific antigen (PSA) follow-up period, were investigated. Immunohistochemical staining of HGF was compared to biochemical recurrence after radical prostatectomy. Patients with tumors exhibiting HGF positivity of 5% or more had a significantly shorter biochemical recurrence-free period than that of patients whose tumor HGF positivity was less than 5% (p=0.001). In multivariate Cox regression, preoperative PSA and HGF positivity were independent predictors of biochemical recurrence following prostatectomy. Our finding suggests a direct link between expression of HGF, a novel prostate marker of CSCs/CICs, and biochemical recurrence after radical prostatectomy in patients with prostate cancer.

    PubMed

  • Prostate cancer stem-like cells/cancer-initiating cells have an autocrine system of hepatocyte growth factor.

    Sachiyo Nishida, Yoshihiko Hirohashi, Toshihiko Torigoe, Ryuta Inoue, Hiroshi Kitamura, Toshiaki Tanaka, Akari Takahashi, Hiroko Asanuma, Naoya Masumori, Taiji Tsukamoto, Noriyuki Sato

    Cancer science   104 ( 4 ) 431 - 6  2013年04月  [国際誌]

    担当区分：   筆頭著者

    　概要を見る

    Prostate cancer cells include a small population of cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) that have roles in initiation and progression of the cancer. Recently, we isolated prostate CSCs/CICs as aldehyde dehydrogenase 1-highh (ALDH1(high) ) cells using the ALDEFLUOR assay; however, the molecular mechanisms of prostate CSCs/CICs are still elusive. Prostate CSCs/CICs were isolated as ALDH1(high) cells using the ALDEFLUOR assay, and the gene expression profiles were analyzed using a cDNA microarray and RT-PCR. We found that prostate CSCs/CICs expressed higher levels of growth factors including hepatocyte growth factor (HGF). Hepatocyte growth factor protein expression was confirmed by enzyme linked immunosorbent assay and Western blotting. On the other hand, c-MET HGF receptor was expressed in both CSCs/CICs and non-CSCs/CICs at similar levels. Hepatocyte growth factor and the supernatant of myofibloblasts derived from the prostate augmented prostasphere formation in vitro, and prostasphere formation was inhibited by an anti-HGF antibody. Furthermore, c-MET gene knockdown by siRNA inhibited the prostasphere-forming ability in vitro and tumor-initiating ability in vivo. Taken together, the results indicate that HGF secreted by prostate CSCs/CICs and prostate myofibroblasts has a role in the maintenance of prostate CSCs/CICs in an autocrine and paracrine fashion.

    DOI PubMed

  • Gene expression profiles of prostate cancer stem cells isolated by aldehyde dehydrogenase activity assay.

    Sachiyo Nishida, Yoshihiko Hirohashi, Toshihiko Torigoe, Hiroshi Kitamura, Akari Takahashi, Naoya Masumori, Taiji Tsukamoto, Noriyuki Sato

    The Journal of urology   188 ( 1 ) 294 - 9  2012年07月  [国際誌]

    担当区分：   筆頭著者

    　概要を見る

    PURPOSE: Prostate cancer cells include a small population of cancer stem-like/cancer initiating cells, which have roles in cancer initiation and progression. Recently aldehyde dehydrogenase activity was used to isolate stem cells of various cancer and normal cells. We evaluated the aldehyde dehydrogenase activity of the human prostate cancer cell line 22Rv1 (ATCC®) with the ALDEFLUOR® assay and determined its potency as prostate cancer stem-like/cancer initiating cells. MATERIALS AND METHODS: The human prostate cancer cell line 22Rv1 was labeled with ALDEFLUOR reagent and analyzed by flow cytometry. ALDH1(high) and ALDH1(low) cells were isolated and tumorigenicity was evaluated by xenograft transplantation into NOD/SCID mice. Tumor sphere forming ability was evaluated by culturing in a floating condition. Invasion capability was evaluated by the Matrigel™ invasion assay. Gene expression profiling was assessed by microarrays and reverse transcriptase-polymerase chain reaction. RESULTS: ALDH1(high) cells were detected in 6.8% of 22Rv1 cells, which showed significantly higher tumorigenicity than ALDH1(low) cells in NOD/SCID mice (p < 0.05). Gene expression profiling revealed higher expression of the stem cell related genes PROM1 and NKX3-1 in ALDH1(high) cells than in ALDH1(low) cells. ALDH1(high) cells also showed higher invasive capability and sphere forming capability than ALDH1(low) cells. CONCLUSIONS: Results indicate that cancer stem-like/cancer initiating cells are enriched in the ALDH1(high) population of the prostate cancer cell line 22Rv1. This approach may provide a breakthrough to further clarify prostate cancer stem-like/cancer initiating cells. To our knowledge this is the first report of cancer stem-like/cancer initiating cells of 22Rv1 using the aldehyde dehydrogenase activity assay.

    DOI PubMed

  • Japanese female urologists' work‐life balance during the COVID‐19 pandemic

    Sachiyo Nishida, Hitomi Sasaki, Yoshiko Maeda, Masayuki Koyama, Katsuhito Miyazawa, Naoya Masumori

    International Journal of Urology    2022年12月

    DOI

  • Tumor-infiltrating CD8+ T cells recognize a heterogeneously expressed functional neoantigen in clear cell renal cell carcinoma.

    Masahiro Matsuki, Yoshihiko Hirohashi, Munehide Nakatsugawa, Aiko Murai, Terufumi Kubo, Shinichi Hashimoto, Serina Tokita, Kenji Murata, Takayuki Kanaseki, Tomohide Tsukahara, Sachiyo Nishida, Toshiaki Tanaka, Hiroshi Kitamura, Naoya Masumori, Toshihiko Torigoe

    Cancer immunology, immunotherapy : CII   71 ( 4 ) 905 - 918  2022年04月  [国際誌]

    　概要を見る

    Immune checkpoint inhibitors (ICIs) are used in cancer immunotherapy to block programmed death-1 and cytotoxic T-lymphocyte antigen 4, but the response rate for ICIs is still low and tumor cell heterogeneity is considered to be responsible for resistance to immunotherapy. Tumor-infiltrating lymphocytes (TILs) have an essential role in the anti-tumor effect of cancer immunotherapy; however, the specificity of TILs in renal cell carcinoma (RCC) is elusive. In this study, we analyzed a 58-year-old case with clear cell RCC (ccRCC) with the tumor showing macroscopic and microscopic heterogeneity. The tumor was composed of low-grade and high-grade ccRCC. A tumor cell line (1226 RCC cells) and TILs were isolated from the high-grade ccRCC lesion, and a TIL clone recognized a novel neoantigen peptide (YVVPGSPCL) encoded by a missense mutation of the tensin 1 (TNS1) gene in a human leukocyte antigen-C*03:03-restricted fashion. The TNS1 gene mutation was not detected in the low-grade ccRCC lesion and the TIL clone did not recognized low-grade ccRCC cells. The missense mutation of TNS1 encoding the S1309Y mutation was found to be related to cell migration by gene over-expression. These findings suggest that macroscopically and microscopically heterogenous tumors might show heterogenous gene mutations and reactivity to TILs.

    DOI PubMed

全件表示 >>

このページの先頭へ▲

Misc 【 表示 ／ 非表示 】

  • 当院におけるRARP200例の治療成績

    柴森 康介, 佐藤 俊介, 吉川 友博, 桧山 佳樹, 松木 雅裕, 西田 幸代, 伊藤 直樹

    泌尿器外科 ( 医学図書出版(株) )  36 ( 5 ) 426 - 426  2023年05月

  • 当院におけるRARP200例の治療成績

    柴森 康介, 佐藤 俊介, 吉川 友博, 桧山 佳樹, 松木 雅裕, 西田 幸代, 伊藤 直樹

    泌尿器外科 ( 医学図書出版(株) )  36 ( 5 ) 426 - 426  2023年05月

  • JUAの女性座長リスト企画の経緯と真意

    佐々木 ひと美, 西田 幸代, 小林 知子, 山本 泰代, 前田 佳子, 松下 千枝, 高橋 さゆり, 増田 朋子, 松本 富美, 川崎 麻巳, 久米 春喜, 舛森 直哉, 宮澤 克人, 日本泌尿器科学会ダイバーシティ推進委員会・女性座長候補者リスト作成ワーキンググループ

    日本泌尿器科学会総会 ( (一社)日本泌尿器科学会総会事務局 )  110回   np3 - np3  2023年04月

  • あなたならどうする?～腹腔鏡下摘除術のトラブルシューティング～ 腹腔鏡下手術トラブル "I'm safe is NOT safe"と気づいたら

    西田 幸代, 舛森 直哉

    日本泌尿器内視鏡・ロボティクス学会総会 ( (一社)日本泌尿器内視鏡・ロボティクス学会 )  36回   SY - 1  2022年11月

  • ダイバーシティ 女性泌尿器科医の活躍に対する施策

    宮澤 克人, 野口 満, 中川 徹, 西田 幸代, 吉川 武志, 東武 昇平, 増田 朋子

    日本泌尿器科学会雑誌 ( (一社)日本泌尿器科学会 )  113 ( Suppl. ) S136 - S139  2022年11月

全件表示 >>

このページの先頭へ▲

受賞 【 表示 ／ 非表示 】

  • 令和3年度学術賞

    2022年07月   札幌医科大学医師会  

  • 第15回稲田賞症例報告部門

    2022年06月   泌尿器科紀要編集部   難治性低カルシウム・低リン血症をきっかけにFGF23高値を指摘された前立腺癌多発骨転移の1例  

このページの先頭へ▲

共同研究・競争的資金等の研究課題 【 表示 ／ 非表示 】

  • 男性比率の高い領域での女性活躍推進：医学生の診療科選択の現状と課題

    基盤研究(B)

    研究期間:

    2023年04月
    -
    2028年03月
     

    臼井 恵美子, 西田 幸代, 松倉 力也, 中村 さやか, 奥村 綱雄

  • 前立腺がん幹細胞の同定と特異的がんワクチン療法の樹立

    基盤研究(C)

    研究期間:

    2012年04月
    -
    2015年03月
     

    舛森 直哉, 北村 寛, 西田 幸代

    　研究概要を見る

    本研究の目的は前立腺癌のがん幹細胞の同定と解析および治療法の樹立である。ヒト前立腺癌細胞株22Rv1に対してALDH1活性分析を行ったところ、ALDH1活性の高い細胞集団にがん幹細胞が多く含まれ、hepatocyte growth factor(HGF)を分泌することがわかった。前立腺癌患者の摘出標本のHGF免疫染色を行い術後のPSA再発との関係を調べた結果、HGF陽性率5%以上の症例群は5%未満の症例に比較し有意にPSA再発までの期間が短かった。HGFの抑制が癌の再発回避につながる可能性がある。

このページの先頭へ▲
 

委員歴 【 表示 ／ 非表示 】

  • 2024年02月
    -
    継続中

      がん診療ガイドライン評価委員会

  • 2023年04月
    -
    継続中

      広報委員会

  • 2023年04月
    -
    継続中

      会則検討委員会

  • 2022年11月
    -
    継続中

      日本泌尿器内視鏡・ロボティクス学会 教育委員会委員

  • 2022年11月
    -
    継続中

      日本排尿機能学会ダイバーシティ推進委員会委員

全件表示 >>

このページの先頭へ▲